Evidence map›Paper›PMID 39926109›Full record

Article3 Biotech2025

Evaluation of a chloroquine hydrogel for topical treatment of leishmaniasis in BALB/c mice infected with

Arlindo Gonzaga Branco Junior, Saara Neri Fialho, Aurileya de Jesus Gouveia, Amália Dos Santos Ferreira, Leandro Do Nascimento Martinez, Welington da Silva Paula do Nascimento, Norton Rubens Diunior Lucas Pejara Rossi, Minelly Azevedo da Silva, Mariana Francy Malaquias Lemke, Karine Modolon Zepon and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arlindo Gonzaga Branco JuniorPrograma de Pós-Graduação em Biodiversidade e Biotecnologia da Amazônia Legal-BIONORTE, Porto Velho, Rondônia Brazil.
Saara Neri FialhoPlataforma de Bioensaios de Malária e Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, Rondônia Brazil.
Aurileya de Jesus GouveiaPlataforma de Bioensaios de Malária e Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, Rondônia Brazil.
Amália Dos Santos FerreiraPlataforma de Bioensaios de Malária e Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, Rondônia Brazil.
Leandro Do Nascimento MartinezPlataforma de Bioensaios de Malária e Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, Rondônia Brazil.ORCID 0000-0003-0887-4784
Welington da Silva Paula do NascimentoPrograma de Pós-Graduação em Biodiversidade e Biotecnologia da Amazônia Legal-BIONORTE, Porto Velho, Rondônia Brazil.
Norton Rubens Diunior Lucas Pejara RossiPlataforma de Bioensaios de Malária e Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, Rondônia Brazil.
Minelly Azevedo da SilvaInstituto Federal de Educação, Ciência e Tecnologia de Rondônia-IFRO, Porto Velho, Rondônia Brazil.
Mariana Francy Malaquias LemkeCentro Universitário Aparício Carvalho-FIMCA, Porto Velho, Rondônia Brazil.
Karine Modolon ZeponUniversidade Do Sul de Santa Catarina-UNISUL, Tubarão, Santa Catarina Brazil.
Luiz Alberto KanisIndustria Farmacêutica Airela, Pedras Grandes, Santa Catarina Brazil.
Laerth Dos Santos RibeiroPlataforma de Bioensaios de Malária e Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, Rondônia Brazil.
Carolina Bioni Garcia TelesPrograma de Pós-Graduação em Biodiversidade e Biotecnologia da Amazônia Legal-BIONORTE, Porto Velho, Rondônia Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis, a challenging disease to treat due to the intracellular location of the parasite and host immune modulation, requires innovative treatment solutions. This study evaluates a chloroquine-based hydrogel for topical use, targeting a localized and less invasive approach to leishmaniasis treatment. Thus, this study aimed at evaluating the skin permeation potential of the antimalarial chloroquine and also to evaluate the less invasive, topical treatment in murine models infected by

Indexed as

ChloroquineHydrogelLeishmania spp.Transdermal treatment

Identifiers

PMID39926109
PMCPMC11799487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.